lactollin

The proposed mechanism centers on milk-basic-protein-like peptides interacting with bone-forming (osteoblast) and bone-resorbing (osteoclast) cells. Some related milk-derived peptide fractions have shown the ability to stimulate osteoblast proliferation and inhibit osteoclast activity in cell-culture and small animal studies. In humans, the published evidence specifically labeled 'lactollin' is sparse and product-specific. The broader category of milk basic protein has limited but mostly favorable small trials showing modest improvements in bone mineral density markers, but lactollin as a uniquely defined molecule is not well documented in peer-reviewed literature.

There is no established dosage. Product labels typically suggest 40 to 100 mg per day. DSLD label data are insufficient to derive a reliable typical dose.

No specific timing data are available. Like other milk-derived peptides, lactollin can be taken with or without food. Bone-supportive supplements are typically taken daily for several months before any change in bone markers would be expected.

As a milk-derived product, lactollin should be well tolerated in people without milk protein allergy. There is little long-term human safety data specific to lactollin. People with severe milk allergy should avoid the product. Lactose-intolerant individuals are usually unaffected because lactose levels in protein fractions are low, but check the label.

No significant pharmacological interactions are reported. Theoretically, high calcium-binding capacity could affect absorption of some minerals or tetracycline antibiotics if taken together, but this is not clinically described.